James Kaye, MD, DrPH
Adjunct Associate Professor
Boston University School of Public Health
Dept of Epidemiology

MD, Stanford University School of Medicine
DPH/DrPH, Harvard School of Public Health
MPH, Harvard School of Public Health

James Kaye, MD, DrPH, is a medical oncologist/hematologist, epidemiologist, and Senior Director of Epidemiology at RTI-HS. Dr. Kaye completed an internship and residency in internal medicine at the Beth Israel Hospital in Boston and a fellowship in medical oncology/hematology at the Dana Farber Cancer Institute. He then served on the faculty in the Department of Medicine at Harvard Medical School while practicing medical oncology/hematology and coordinating the clinical research program at Harvard Community Health Plan.

In 1991, Dr. Kaye joined the clinical development group at Genetics Institute, Inc. (later Wyeth, now Pfizer) where he directed clinical trials on several hematology/oncology products, two of which were approved for marketing. He participated in numerous Food and Drug Administration interactions, including investigational new drug and biologic license application submissions, advisory committee presentations, and label negotiations.

Dr. Kaye subsequently completed doctoral training in pharmacoepidemiology with a focus on pharmaceuticals and cancer risk. He was senior epidemiologist at the Boston Collaborative Drug Surveillance Program and a faculty member at Boston University School of Public Health, where he continues to serve as adjunct associate professor of epidemiology.

In 2009, Dr. Kaye joined RTI-HS, where he conducts research on postmarketing safety issues (especially cancer risk) and advises RTI-HS staff on a variety of health economics, biostatistics, and other projects relating to hematology/oncology drugs in development. He has chaired or participated in numerous independent data monitoring committees for clinical trials of drugs for the treatment of cancer or hematologic diseases, and he consults with clients on the assessment of cancer-related safety issues for drugs used in other indications. Dr. Kaye has authored more than 100 articles in the peer-reviewed medical literature.

Senior Director, Epidemiology
RTI Health Solutions

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020 Sep 14; 1-12. PMID: 32755262
  2. Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma. Clinicoecon Outcomes Res. 2020; 12:317-325. PMID: 32606848
  3. Vassilev ZP, Gabarró MS, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtälä J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncol. 2020 Sep; 16(25):1889-1901. PMID: 32515225
  4. Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, García-Foncillas J, Candrilli SD, Kaye JA. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care (Engl). 2020 Mar; 29(2):e13213. PMID: 31883156
  5. Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019 Aug; 10(4):674-687. PMID: 31392048
  6. Kawai AT, Martinez D, Saltus CW, Vassilev ZP, Soriano-Gabarró M, Kaye JA. Incidence of Skeletal-Related Events in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US. Prostate Cancer. 2019; 2019:5971615. PMID: 31360552
  7. Saltus CW, Vassilev ZP, Zong J, Calingaert B, Andrews EB, Soriano-Gabarró M, Kaye JA. Corrigendum to "Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States". Prostate Cancer. 2019; 2019:3425982. PMID: 31355002
  8. Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer. Curr Med Res Opin. 2019 10; 35(10):1699-1710. PMID: 31060392
  9. Kabadi SM, Goyal RK, Nagar SP, Kaye JA, Davis KL. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019 07; 8(8):3803-3810. PMID: 31144473
  10. Vickers AD, Winfree KB, Cuyun Carter G, Kiiskinen U, Jen MH, Stull D, Kaye JA, Carbone DP. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2019 Apr 15; 19(1):353. PMID: 30987609
Showing 10 of 113 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 113 publications over 24 distinct years, with a maximum of 17 publications in 2018


Contact for Mentoring:

RTI Health Solutions, 307 Waverley Oaks Road, Suite 101
Waltham MA 02452-8413
Google Map

Kaye's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department